A Glimpse of Zhongguancun Life Science Park
Zhongguancun Life Science Park, as an important support for the main platform of Beijing International Technology Innovation Center” consisting of Zhongguancun Science City, Huairou Science City, Changping Future Science City as well as Yizhuang Economic and Technological Development Zone, is a highland for the development of pharmaceutical and health industry that integrates four state-level functional zones, that is, Zhongguancun Independent Innovation Demonstration Zone, National Comprehensive Demonstration Zone for the Expansion and Opening-up of the Service Industry, Free Trade Pilot Zone, and the core area of high-level talents in Beijing. After 20 years of development, the Park has attracted multiple state-level research and development institutions to have their presence here, brought together a group of globally top scientists and hundreds of high-level talents. There are more than 600 innovative pharmaceutical enterprises and over 300 high-end talents, including 21 academicians, 4 scholars supported by the Cheung Kong Scholars Programme, 50+ personnel entitled to special allowance from the State Council, 7 academician workstations, 20+ post-doctoral research centers, 10+ national engineering research centers and key laboratories, 16 R&D centers at provincial and ministerial level, and nearly 3,000 sickbeds in the medical institutions, thus forming the trend of bringing together the whole industry chain including basic research, R&D pilot test, production and circulation, and terminal healthcare. It has been built into one of the parks with the most concentrated innovation resources in the field of life science in China, which is an innovation engine for the development of the pharmaceutical and health industry in Beijing.
300 +
High-end talents
600 +
Innovative pharmaceutical enterprises
7 +
Academician workstations
21 +
Post-doctoral research centers
10 +
Academician workstations
16
R&D centers at provincial and ministerial level
INDUSTRYGROUP
INNOVATIONPLATFORM
Beijing Zhongguancun Life Science Park Biomedicine Technology Incubation Co., Ltd. is a professional incubator specializing in the field of biomedicine. Since its establishment, it has received dozens of licensing and qualifications granted by the government. In addition, it undertakes work related to Overseas Students Pioneer Park at Beijing Zhongguancun Life Science Park and the IPR Public Service Workstation at Changping District Life Science Park, offering incubation service for more than 140 well-known startup companies in the industry, such as BeiGene, Crown Bioscience, BerryGenomics, Novogene, Sironax, Biocytogen, MyGenostics, etc.
The international incubator ATLATL, a high-end platform for the acceleration of innovation projects, which aligns with the standards of top international biopharmaceutical R&D centers, initiated by Dr. Zhu Pengcheng, focusing on key subdivisions and emerging technology fields such as cell and gene therapy, miRNA, gene editing and synthetic biology. By introducing professional research teams, it aims to build a base for double transformation in international cooperation on cutting-edge technology and the industrialization of R&D results. Recently, ATLATL, together with SEQUANTA, has set up a sequencing center to better serve customers and contribute to more unicorn companies in Beijing.
Bio2, built and officially put into operation in 2021, focusing on the needs of scientists and entrepreneurs, puts emphasis on the transformation of early results in life and health and business incubation. Relying on the combined advantages of “professional carrier platform + abundant funding channels + active interactive information base”, Bio2 provides start-up teams with ready-to-use shared office space and professional shared experimental sites. At present, nearly 30 potential projects with global leading technologies have been reserved, and 44 innovation-oriented enterprises such as Sironax, Neural Galaxy, Shuimu Biosciences, Pulmongene Ltd., and Simcere have settled here.
Changping Life Valley Marathon Digital Medical Incubator is China’s first digital medical business incubator jointly initiated by BC-TID, Zhongguancun Life Science Park and Marathon Venture Partners. With the vision of making investment for accelerating the new generation of digital medical entrepreneurs and promoting global digital medical industry-university-research innovation, the incubator will focus on the development direction of digital healthcare and smart healthcare, such as AI healthcare, medical robot, genomics, digital therapy, insurance technology, committed to making full cooperation with the world’s top parks, medical centers, scientific research institutions and other ecological partners.
2024-08-06
企业资讯丨mNGS室间质评结果发布,博奥检验连续5年全面通过感染领域多项质评
企业资讯丨诺灵生物入板北京股权交易中心“专精特新”专板
近日,中关村生命科学园内企业 诺灵生物 获得北京股权交易中心接纳, 。 预计阅读时间:2分钟 诺灵生物专注于新一代ADC的研发,自研了源头创新的、差异化的linker和毒素技术。今年年初,诺灵生物宣布 已完成数千万元人民币的 B1轮融资 与 NC18 在 两国IND申报两大里程碑。 NC18 采用了全新linker和payload,该组合展现出良好的活性、可控的旁杀效应、更好的抗耐药性, 具有更好...
会议活动丨2024 Co-Lab科研引擎第四站!毛细管电泳技术与应用研讨会
中关村生命科学园共享技术平台(简称“Co-Lab”)已配置全新设备:MauriceTM CE-SDS、全柱成像毛细管等电聚焦电泳(iCIEF)双功能毛细管电泳系统,该设备具有CE-SDS、iCIEF双模式检测、免组装毛细管卡盒、双模式一键切换、程序一键设定、数据一键分析等特点。2024年8月7日至8日,Co-Lab平台将邀请技术专家开展毛细管电泳技术与应用研讨会,为企业提供高品质技术服务的同时,配...
普沐生物揭示肺纤维化全新靶点作用机制,靶点新药PMG1015带来治疗新希望!
8月2日,中关村生命科学园内企业 普沐生物 与 Cell Stem Cell 上发表研究论文。 该研究系统性地阐述了公司开发用于治疗特发性肺纤维化(Idiopathic Pulmonary Fibrosis,IPF)的 ,并且通过在IPF病人上的转化医学研究明确了AREG与IPF发生发展的密切关系。 本研究的相关发现不仅揭示了IPF发病的新机制,发现了新靶点,也证实了靶点拮抗剂在临床前模型中的药效...